Clinical Trial Detail

NCT ID NCT04177108
Title A Study Of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer.
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

triple-receptor negative breast cancer

Therapies

Ipatasertib + Paclitaxel

Atezolizumab + Paclitaxel

Atezolizumab + Ipatasertib + Paclitaxel

Paclitaxel

Age Groups: adult senior

No variant requirements are available.